Drugs / MDG1021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04464889 | Jul 2020 → Jul 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome +2 | MediGene | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDG1021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04464889 ↗ |
| Action | Deplete | “MDG1021 immunotherapy could eradicate the patient's cancer cells” NCT04464889 ↗ |
| Modality | Cell therapy | “a HLA-A\*02:01 restricted, HA-1H T cell receptor (TCR) transduced patient-derived T cell (MDG1021) immunotherapy” NCT04464889 ↗ |
| Route | Intravenous | “MDG1021 will be administered by single intravenous infusion” NCT04464889 ↗ |